Literature DB >> 17503664

New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc.

Gaël Champier1, Sébastien Hantz, Anthony Couvreux, Stéphanie Stuppfler, Marie-Christine Mazeron, Serge Bouaziz, François Denis, Sophie Alain.   

Abstract

INTRODUCTION: Benzimidazole D-ribonucleosides inhibit DNA packaging during human cytomegalovirus (HCMV) replication. Although they have been shown to target pUL56 and pUL89, the large and small subunits of the HCMV terminase respectively, their mechanism of action is not yet fully understood. METHODS AND
RESULTS: To better understand HCMV DNA maturation and the mechanism of action of benzimidazole derivatives, we studied the HCMV pUL89 protein by a genetic approach combined with primary structure analysis. The pUL89 sequence analysis of 25 HCMV strains and counterparts among herpesviruses allowed identification of 12 conserved regions. We also built a three-dimensional model of the pUL89 ATPasic catalytic site, including ATPase motor motifs 1, II and III, that may facilitate the development of future antiviral drugs active against HCMV. Finally, we identified several putative functional domains in pUL89, such as pUL89 zinc finger (pUL89-ZF), DNA cutting sites and portal binding sites, that are probably involved in CMV DNA cleavage and packaging.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17503664

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  12 in total

1.  Structure and inhibition of herpesvirus DNA packaging terminase nuclease domain.

Authors:  Marta Nadal; Philippe J Mas; Phillipe J Mas; Alexandre G Blanco; Carme Arnan; Maria Solà; Darren J Hart; Miquel Coll
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-30       Impact factor: 11.205

2.  Investigational Antiviral Therapy Models for the Prevention and Treatment of Congenital Cytomegalovirus Infection during Pregnancy.

Authors:  Stuart T Hamilton; Manfred Marschall; William D Rawlinson
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

3.  Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds.

Authors:  Sunwen Chou
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

4.  Mutual Interplay between the Human Cytomegalovirus Terminase Subunits pUL51, pUL56, and pUL89 Promotes Terminase Complex Formation.

Authors:  Sebastian Neuber; Karen Wagner; Thomas Goldner; Peter Lischka; Lars Steinbrueck; Martin Messerle; Eva Maria Borst
Journal:  J Virol       Date:  2017-05-26       Impact factor: 5.103

5.  Role of channel lysines and the "push through a one-way valve" mechanism of the viral DNA packaging motor.

Authors:  Huaming Fang; Peng Jing; Farzin Haque; Peixuan Guo
Journal:  Biophys J       Date:  2012-01-03       Impact factor: 4.033

6.  Divergent Evolution of Nuclear Localization Signal Sequences in Herpesvirus Terminase Subunits.

Authors:  Rajeshwer S Sankhala; Ravi K Lokareddy; Gino Cingolani
Journal:  J Biol Chem       Date:  2016-03-31       Impact factor: 5.157

7.  Antiviral Drugs Against Herpesviruses.

Authors:  Jocelyne Piret; Guy Boivin
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

8.  Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure.

Authors:  Thomas Goldner; Christine Hempel; Helga Ruebsamen-Schaeff; Holger Zimmermann; Peter Lischka
Journal:  Antimicrob Agents Chemother       Date:  2013-11-04       Impact factor: 5.191

9.  Dominant-negative proteins in herpesviruses - from assigning gene function to intracellular immunization.

Authors:  Hermine Mühlbach; Christian A Mohr; Zsolt Ruzsics; Ulrich H Koszinowski
Journal:  Viruses       Date:  2009-10-19       Impact factor: 5.048

Review 10.  Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus.

Authors:  Dante P Melendez; Raymund R Razonable
Journal:  Infect Drug Resist       Date:  2015-08-05       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.